1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
TFBS Bioscience, Inc.

TFBS Bioscience, Inc.

TTPEX:6939
18.80
TWD
+0.15
(+0.80%)
707.98MMarket Cap
TFBS Bioscience, Inc.
TPEX:6939
(Taipei Exchange)

Recent

price

18.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
TWD
3.41
12.41
8.82
6.69
5.18
5.53
- -
Revenue per Share
0.01
0.47
0.97
0.14
-1.11
-2.13
- -
Basic EPS, GAAP
0.46
0.15
1.01
-0.56
-9.87
-6.73
- -
Free Cash Flow per Basic Share
- -
- -
- -
0.1
0.05
- -
- -
Dividend per Share
7.13
12.21
35.56
36.23
35.3
33.24
32.05
Book Value per Share
6.15
11.33
34.76
35.51
34.66
32.7
31.55
Tangible Book Value per Share
35
13
29
35
35
35
35
Basic Weighted Avg Shares
119
161
253
232
181
193
- -
Sales/Revenue/Turnover
0.26
3.73
13.36
-1.92
-33.91
-40.39
- -
Operating Margin (%)
25
25
37
59
50
52
- -
Depreciation Expense
- -
6
28
5
-39
-75
- -
Net Income, GAAP
11.38
12.64
9.82
- -
- -
- -
- -
Effective Tax Rate (%)
0.25
3.81
10.96
2.12
-21.42
-38.58
- -
Profit Margin (%)
78
258
1,009
988
588
323
293
Working Capital
14
16
22
102
76
94
81
LT Debt
248
425
1,237
1,261
1,233
1,164
1,134
Total Equity
- -
1.47
2.79
- -
- -
- -
- -
Return on Invested Capital (%)
- -
1.79
3.26
- -
- -
- -
- -
Return on Capital (%)
- -
1.82
3.33
0.39
-3.1
-6.22
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
129
131
129
LT Borrowings
- -
- -
- -
LT Finance Leases
65
94
81
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
791
749
708

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
642
523
503
Cash, Cash Equivalents & STI
547
441
395
Accounts Receivable, Net
36
24
35
Inventories
8
14
26
Total Current Liabilities
264
200
209
Payables & Accruals
- -
- -
- -
ST Debt
129
131
129
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
51.33%
-5.57%
Free Cash Flow
- -
549.81%
-31.63%
Net Income, GAAP
- -
288.7%
92.69%
Sales/Revenue/Turnover
- -
13.87%
6.97%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
181
2025
- -
- -
193
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.11
2025
- -
- -
-2.13
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.05
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
TFBS Bioscience Inc. functions as a specialized contract research and manufacturing organization based in New Taipei City, Taiwan. The company delivers advanced viral vector production services, encompassing adeno-associated virus, lentivirus, and retrovirus types, crucial for the development of cell and gene therapy products. Additionally, it offers comprehensive biosafety assessments and product release verification for various cell and gene therapies, vaccines, and other biological therapeutics. Established in 2016 with foundational expertise from a government research institute, TFBS Bioscience continues to expand its integrated, GMP-compliant solutions, recently forging strategic alliances with international partners to enhance global reach in manufacturing and quality control testing.